Japan· JP-1162001F1066
ビペリデン塩酸塩
A biperiden product containing ビペリデン塩酸塩, registered in Japan by 住友ファーマ, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Biperiden is registered in 15 of 19 countries.
Countries holding a registration under ATC N04AA02 (biperiden), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Biperiden · ATC N04AA02
15 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of biperiden costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.28 in France to $1.58 in Switzerland — a ×5.7 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Biperiden · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.58
- IT Italy$0.36
- FR France$0.28
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ビペリデン塩酸塩
- Manufacturer
- 住友ファーマ
- Country
- Japan (JP)
- ATC code
- N04AA02
- ATC class
- Biperiden
- Defined daily dose
- 10 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
89 interactions on record for biperiden.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Biperiden · interactions on record
89 records
- 3 severe
- 85 moderate
- 1 minor
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Potassium chlorideB05XA01severe
- DicycloverineA03AA07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N04AA02
Biperiden, as other registers publish it.
- PolandAkinetonDesma GmbH
- PolandAkinetonDesma GmbH
- IcelandAkinetonLaboratorio Farmaceutico Specialitá Igienico Terapeutiche (S.I.T.) S.r.L.
- GermanyAkinetonDesma Gmbh
- FinlandAkinetonLaboratorio Farmaceutico S.I.T S.r.l.
- NorwayAkinetonLaboratorio Farmaceutica S.I.T. Srl
- GermanyAkinetonDesma Gmbh
- NorwayAkinetonLaboratorio Farmaceutico S.I.T. Srl, NUF
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b61838c8-98dc-4ffc-b63e-c97ef8ba020f GET /v1/drugs/b61838c8-98dc-4ffc-b63e-c97ef8ba020f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1162001F1066",
"category": "内用薬",
"price_yen": 6.1,
"generic_name": "ビペリデン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1162",
"transitional_expiry": null
}See everything about biperiden.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.